We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IQVIA (IQV) Announces Launch of Clinical Data Analytics Suite
Read MoreHide Full Article
IQVIA Holdings Inc. (IQV - Free Report) today unveiled a SaaS-based data analytics platform, Clinical Data Analytics Suite (“CDAS”). The platform is usable in clinical, operational and real-world analytics.
CDAS is a part of IQVIA Technologies’ Orchestrated Clinical Trials (“OCT”), which is an end-to-end, patient-centric platform that provides data infrastructure and connectivity.
The platform, using artificial intelligence and machine learning, converts descriptive data from clinical trials to analytical insights, and facilitates easier access and utilization. It automates delivery of data intelligence to clinical trial workflows, and can be used together with the rest of the OCT solutions and existing data archives and systems.
The platform brings a wide gamut of benefits for users, including real-time data management, reduced data harmonization efforts, reduced time of KPI deployment, improved decision making and reduced of R&D cost.
Nagaraja Srivatsan, chief digital officer of Research and Development Technology Solutions, IQVIA, stated, "Sponsors need an open platform to ingest all trial data, including real world data, and to standardize it into useful models. The Clinical Data Analytics Suite supports exploration of information on demand and unlocks previously hidden insights across systems."
Notably, IQVIA shares have gained a massive 74.8% over the past year, significantly outperforming the 12.7% rally of the industry it belongs to.
The long-term expected earnings per share (three to five years) growth rate for Trane Technologies, Cross Country Healthcare and Charles River is pegged at 21.5%, 10.5% and 15.5%, respectively.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Image: Bigstock
IQVIA (IQV) Announces Launch of Clinical Data Analytics Suite
IQVIA Holdings Inc. (IQV - Free Report) today unveiled a SaaS-based data analytics platform, Clinical Data Analytics Suite (“CDAS”). The platform is usable in clinical, operational and real-world analytics.
CDAS is a part of IQVIA Technologies’ Orchestrated Clinical Trials (“OCT”), which is an end-to-end, patient-centric platform that provides data infrastructure and connectivity.
The platform, using artificial intelligence and machine learning, converts descriptive data from clinical trials to analytical insights, and facilitates easier access and utilization. It automates delivery of data intelligence to clinical trial workflows, and can be used together with the rest of the OCT solutions and existing data archives and systems.
The platform brings a wide gamut of benefits for users, including real-time data management, reduced data harmonization efforts, reduced time of KPI deployment, improved decision making and reduced of R&D cost.
Nagaraja Srivatsan, chief digital officer of Research and Development Technology Solutions, IQVIA, stated, "Sponsors need an open platform to ingest all trial data, including real world data, and to standardize it into useful models. The Clinical Data Analytics Suite supports exploration of information on demand and unlocks previously hidden insights across systems."
Notably, IQVIA shares have gained a massive 74.8% over the past year, significantly outperforming the 12.7% rally of the industry it belongs to.
IQVIA Holdings Inc. Price
IQVIA Holdings Inc. price | IQVIA Holdings Inc. Quote
Zacks Rank and Stocks to Consider
IQVIA currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader Zacks Business Services sector includes Trane Technologies (TT - Free Report) , Cross Country Healthcare (CCRN - Free Report) and Charles River Associates (CRAI - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
The long-term expected earnings per share (three to five years) growth rate for Trane Technologies, Cross Country Healthcare and Charles River is pegged at 21.5%, 10.5% and 15.5%, respectively.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How to Profit from Trillions on Spending for Infrastructure >>